# Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

> **NCT04049539** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 28 (estimated)

## Conditions studied

- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
- Persistent Disease
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine

## Key facts

- **NCT ID:** NCT04049539
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049539, "Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04049539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*